Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Clinical Study to Evaluate the Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

NCT07526493 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07526493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07526493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Clinical Study to Evaluate the Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Lead sponsor
Tongji Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
April 1, 2026
Completion date
December 31, 2028
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-myelin oligodendrocyte glycoprotein immunoglobulin g antibody-associated disease (mogad), autoimmune encephalitis (ae), chronic inflammatory demyelinating polyneuropathy (cidp), idiopathic inflammatory myopathies (iim), multiple sclerosis (ms), myasthenia gravis (mg), neuromyelitis optica spectrum disorder (nmosd)